Five to 11-year-olds are a step closer to being eligible for a COVID-19 vaccine in the United States.
Federal health officials are expected to sign off soon on a vaccine for this age group. That authorization passed its first hurdle October 26 when an advisory panel to the U.S. Food and Drug Administration gave their thumbs-up to make Pfizer’s and its German partner BioNTech’s vaccine available to 5- to 11-year-olds.
The decision to endorse emergency use authorization of the vaccine followed an extensive discussion among experts on the advisory panel, who were tasked with determining if the vaccine’s benefits outweigh the risks.
Many panelists, for instance, expressed concerns about
→ Continue reading at Science News